{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 25 of 92', 'CR845-CLIN3102', 'maximum concentration and area under the curve, and minimal to no accumulation with', \"repeat doses due to clearance of the drug by hemodialysis (see Investigator's Brochure\", 'for details).', '4.3', 'Summary of Potential Risks and Benefits', 'During preclinical development, no specific safety findings to preclude the use of CR845', 'in humans were observed. During early clinical development, IV CR845 was', 'administered to healthy volunteers; patients with mild, moderate, or severe renal', 'impairment, including end-stage renal disease (ESRD) and hemodialysis patients;', 'recreational poly-drug users; and postsurgical patients. The effects of CR845 have been', 'shown to be in line with the underlying pharmacological mechanism of KOR activity.', 'Consistent with the nonclinical abuse liability studies conducted to date, the results of an', 'abuse-potential study in humans indicated that CR845 appears to present a low risk for', 'abuse potential in humans in comparison to currently clinically used opioids.', 'Overall, tingling/numbness, dizziness, fatigue and/or drowsiness/somnolence have been', 'the most common adverse events. Precaution is recommended in the operation of', 'machinery for patients who experience dizziness, fatigue, and/or drowsiness/somnolence.', 'This is described in the informed consent form (ICF), as appropriate, and will be', 'discussed with each patient prior to initiation of the study. In general, CR845 appeared to', 'be well tolerated in both single- and repeat-dose clinical studies, which support continued', 'study and development of this compound.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 27 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 26 of 92', 'CR845-CLIN3102', '5.0', 'Objectives', 'Primary Objective', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared to', 'placebo in reducing the intensity of itch in hemodialysis patients with', 'moderate-to-severe pruritus.', 'Secondary Objectives', 'To evaluate the efficacy of IV CR845 at a dose of 0.5 mcg/kg compared', 'to', 'placebo in improving itch-related quality-of-life measures in hemodialysis', 'patients with moderate-to-severe pruritus.', 'To evaluate the safety of IV CR845 at a dose of 0.5 mcg/kg in hemodialysis', 'patients with moderate-to-severe pruritus.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 28 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 27 of 92', 'CR845-CLIN3102', '6.0', 'Investigational Plan', '6.1', 'Overall Study Design and Plan: Description', 'This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the', 'safety and efficacy of IV CR845 at a dose of 0.5 mcg/kg administered after each dialysis', 'session. The study includes a Double-blind Phase and an Open-label Extension Phase.', 'CR845 will be evaluated relative to placebo over a 12-week Double-blind Treatment', 'Period in hemodialysis patients with moderate-to-severe pruritus followed by a 2-week', 'monitored Discontinuation Period. At the end of the Discontinuation Period, patients', 'who received at least 30 doses of study drug during the 12-week Double-blind Treatment', 'Period will have the option to receive open-label CR845 for an additional 52 weeks.', '6.1.1', 'Double-blind Phase', 'The Double-blind Phase of the study will consist of a Screening Visit, a 7-day Run-in', 'Period, a 12-week Double-blind Treatment Period, and a 2-week Discontinuation Period.', 'Informed consent will be obtained prior to performing any study-specific procedures.', 'The Screening Visit will occur within 7 to 28 days prior to randomization in order to', 'assess eligibility. The Screening Visit can be conducted during the Run-in Period at the', 'discretion of the Investigator.', '6.1.1.1', 'Screening Visit', 'During the Screening Visit, patients will sign the Informed Consent, and will be', 'evaluated for eligibility by assessment of inclusion/exclusion criteria, medical history,', 'physical examination, prescription dry body weight, pre-dialysis 12-lead', 'electrocardiogram, pre-dialysis vital signs, pre-dialysis hematology and serum chemistry,', 'serum pregnancy test for females of childbearing potential, adverse events, and ESA and', 'IV iron doses, and prior medications.', '6.1.1.2', 'Run-in Period', 'Eligible patients will complete a 7-day Run-in Period during the week prior to', 'randomization to confirm eligibility, starting on the first dialysis session of that week', '(ie, Monday for patients on a Monday-Wednesday-Friday dialysis schedule or Tuesday', 'for patients on a Tuesday-Thursday-Saturday dialysis schedule). The purpose of the', 'Run-in Period will be to confirm that each patient has moderate-to-severe pruritus', '(ie, weekly average score >4), as measured by the 24-hour Worst Itching Intensity NRS,', 'and to establish a baseline itch intensity. These criteria for eligibility should not be', \"communicated to the patients. This period will also be used to record each patient's use\", 'of itch medications.', 'During the first visit of the Run-in Period, patients will be trained on completion of the', '24-hour Worst Itching Intensity NRS scale and will start the reporting of their Worst', 'Itching Intensity NRS daily score. For consistency, patients will be requested to', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 29 of 95']\n\n###\n\n", "completion": "END"}